近日,美国感染病学会(IDSA)发布了《IDSA 2024抗微生物耐药革兰阴性菌治疗指引》(IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections),为临床医生提供了宝贵的治疗参考。该文件主要针对产超广谱β-内酰胺酶肠杆目细菌(ESB...
近日,美国感染病学会(IDSA)发布了《IDSA 2024抗微生物耐药革兰阴性菌治疗指引》(IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections),为临床医生提供了宝贵的治疗参考。该文件主要针对产超广谱β-内酰胺酶肠杆目细菌(ESBL-E)、产AmpC β-内酰胺酶肠杆目细菌(AmpC-E)、碳青...
近期,美国感染病学会(IDSA)更新发布了2023版的《抗微生物耐药革兰阴性细菌感染的治疗指引》(IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections),现整理相关建议内容如下。该“指南”实为指引文件,则与国内实践有所差异;且本文编译可能有所误差或纰漏,请以原文为准参考。 登录以...
近日,美国感染病学会(IDSA)发布了《IDSA 2024抗微生物耐药革兰阴性菌治疗指引》(IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections),为临床医生提供了宝贵的治疗参考。该文件主要针对产超广谱β-内酰胺酶肠杆目细菌(ESBL-E)、产AmpC β-内酰胺酶肠杆目细菌(AmpC-E)、碳青...
临床用药评价公众号评:虽然2023年IDSA GUIDELINES《Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections》很具有临床借鉴意义,但国内仍需要谨慎引荐,毕竟这份指南的很多数据基于...
近期,美国感染病学会(IDSA)更新发布了2023版的《抗微生物耐药革兰阴性细菌感染的治疗指引》(IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections),现整理相关建议内容如下。该“指南”实为指引文件,则与国内实践有所差异;且本文编译可能有所误差或纰漏,请以原文为准参考。
培南-西司他丁-雷利巴坦单药治疗。参考⽂献：Tamma PD, Aitken SL, Bonomo RA，et al.Infectious Diseases Society of America Antimicrobial Resistant Treatment Guidance: Gram-Negative Bacterial Infections. Clin Infect Dis. 2020 Oct 27. pii: ciaa1478. doi: 10.1093/cid/ciaa1478.
cUTI:复杂性尿路感染定义为UTIs的发生和生殖泌尿道结构或功能异常相关,或任何男性患者的UTI 非复杂性血流感染包括泌尿系来源,以及拔除感染血管导管的导管相关血流感染 Infectious Diseases Society of America Antimicrobial Resistant Treatment Guidance Gram-Negative Bacterial Infections.pdf 413.8K · 百度网盘...
23. Dinubile MJ,Friedland I,Chan CY,et al.Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections:observations from two randomized comparative clinical trials of ertapenem therapy.Eur J Clin Microbiol Infect Dis,2005,24(7):443-449. 24. Gisk...
The guidelines were reviewed in a session at the American Society of Health-System Pharmacists titled "Beyond the Top Line: A Point-Counterpoint Discussion of the 2020 Antimicrobial Resistant Gram-Negative Infection Treatment Guideline." In part 2 of...